

**Table S1.** Ongoing clinical trials investigating new treatment modalities for localized uveal melanoma. Clinical trials were searched on <https://www.clinicaltrials.gov> and <https://www.clinicaltrialsregister.eu> with terms “uveal melanoma” and “uveal melanoma treatment” on 10/15/2021.

<b>Investigated treatment</b>	<b>Clinical trial</b>	<b>Country</b>	<b>Phase</b>
Autologous dendritic cells loaded with autologous tumor RNA	NCT01983748	Germany	Phase 3
Selumetinib-methyl ethyl ketone (MEK) inhibitor in patients with unresectable uveal melanoma	NCT02768766	USA	Phase 1
Pegylated arginine deiminase (ADI-PEG 20), combined with immunotherapy drugs nivolumab and ipilimumab in patients with unresectable uveal melanoma	NCT03922880	USA	Phase 1
Hypofractionated linear accelerator radiotherapy	NCT00872391	Austria	Not-applicable
Endoresection or transpupillary thermotherapy when endoresection is not feasible in patients with large uveal melanoma	NCT02874040	France	Not-applicable
Intravitreal injection of ICON-1 (human immuno-conjugate 1)	NCT02771340	USA	Phase 1
Stereotactic radiotherapy followed by intravitreal aflibercept injection	NCT03712904	USA	Phase 2
Interferon alfa-2b with dacarbazine in patients with proven monosomy 3 and/or 8q amplification	NCT01100528	USA	Phase 2
Suprachoroidal administration of AU-011 (human papillomavirus virus-like particles conjugated with IR700 dye AU-011) in patients with small choroidal melanoma	NCT04417530	USA	Phase 2
Light-activated AU-011 in patients with small choroidal melanoma	NCT03052127	USA	Phase 1B/2
Ziv-aflibercept (VEGF blocker) in patients with inoperable uveal melanoma	NCT00450255	USA	Phase 2

Autologous dendritic cells loaded with autologous tumor RNA in patients with proven monosomy 3 after surgical resection of uveal melanoma to prolong disease-free survival	2007-007847-28	Germany	Phase 3
--	----------------	---------	---------